Drug intelligence / Profile preview

levonorgestrel

Development stage
Approved
Lead developer
Afaxys
Modality
Small Molecules
Administration
Oral
01

Overview

Levonorgestrel is a synthetic second-generation progestogen that acts as a potent agonist of the progesterone receptor. It is widely utilized in various contraceptive formulations, including emergency contraceptive pills (ECPs), long-acting reversible contraceptives (LARCs) such as intrauterine systems (IUS), and combined oral contraceptive pills. As an emergency contraceptive, it primarily functions by delaying or inhibiting ovulation through the suppression of luteinizing hormone (LH) surges. It may also alter cervical mucus to impede sperm transport and, theoretically, inhibit implantation by altering the endometrium, although the latter mechanism is not the primary mode of action. The brand "Plan A," marketed by Afaxys Pharma, is a 1.5 mg single-dose oral tablet intended for use within 72 hours of unprotected intercourse or contraceptive failure.

Brand names
Plan APlan B One-StepTake ActionMy WayReactOpcicon One-StepHer StyleAfterPillEContra One-StepFallback Solo
Other names
levonorgestrelL-norgestrel
02

Targets

AR (Adrenergic receptors)ESR1 (ERα)PR (Progesterone receptor)

Beyond the preview

Go deeper on levonorgestrel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levonorgestrel.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call